Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data of combination of olanzapine and ondansetron is scarce.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Antiemetics; Aprepitant; BB 1101; Dexamethasone; Dexamethasone acetate; Emetics; Fosaprepitant; Olanzapine; Ondansetron

Criteria

Inclusion Criteria:

• pathologically proved of solid malignancy

• receive first cycle of cisplatin >= 50 mg/m2 or cyclophosphamide/doxorubicin

Exclusion Criteria:

• pregnancy

• patients with episode of vomiting within 24 hours before starting chemotherapy

• uncontrolled brain/ CNS metastasis

• gut obstruction

• receive combination of moderate or high emetogenic chemotherapy during Day 2-5

• Known allergy to ondansetron, olanzapine, aprepitant or dexamethasone

• currently receive olanzapine with other indication and plan to continue the drug